Drug recall
Abacavir/Lamividine, 600/300 MG, Tablets, Distributed by: AidaPak Services, LLC, NDC 00173-0742-00, NDC…
FDA recall event 58901 · Class II · Aidapak Services, LLC
Key facts
| Event ID | 58901 |
|---|---|
| Recall numbers | D-1002-2011, D-1003-2011, D-1004-2011, D-1005-2011, D-1006-2011, D-1007-2011, D-1008-2011, D-1009-2011, D-1010-2011, D-1011-2011, D-1012-2011, D-1013-2011 and 263 more |
| Recalling firm | Aidapak Services, LLC |
| Product type | Drugs |
| Products | Abacavir/Lamividine, 600/300 MG, Tablets, Distributed by: AidaPak Services, LLC, NDC 00173-0742-00, NDC 49702-0206-13, Abacavir/Lamivudine/Zidovudine, 300/150/300 MG, Tablets, Distributed by: AidaPak Services LLC, NDC 00173-0691-00, NDC 49702-0217-18., Abacavir Sulfate, 300 MG, Tablets, Distributed by: AidaPak Services, LLC, NDC 00173-0661-01., Acamprosate Calcium DR, 333 MG, Tablets, Distributed by Aidapak Services LLC, NDC 00456-3330-01., Acarbose, 100 MG, Tablets, Distributed by Aidapak Services LLC, NDC 16252-0525-01. and 270 more |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Firm Initiated |
| Reason for recall | Penicillin Cross Contamination; There is potential for beta-lactam cross contamination of non-penicillin drug products repackaged in the same facility, Penicillin Cross Contamination; There is potential for beta-lactam cross contamination of non-penicillin drug products repackaged in the same facility., Penicillin Cross Contamination; There is potential for beta-lactam cross contamination of… |
| Initiation date | May 19, 2011 |
| Termination date | Apr 18, 2012 |
| City | Vancouver |
| State | WA |
| Country | United States |
| FEI number | 3008673824 |
At a glance
- 100–999 Products in this recall
- 1–9 FDA inspections of this firm (FEI)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug and product recalls
FDA enforcement reports list recalls of drugs, biologics, foods and other FDA-regulated products, classified by the potential health hazard.
Source: U.S. Food and Drug Administration (FDA), Enforcement Reports